Thanks to a new Food and Drug Administration (FDA) approval, an innovative new treatment approach is now available to significantly more men with advanced prostate cancer. The administration expanded ...

On Tuesday the club announced Vicki's passing, after a long battle with ovarian cancer. "During her battle with ovarian cancer, she found joy in viewing your posts and stories and seeing the thriving ...

"Ovarian cancer can affect anybody with ovaries of any age." 23-year-old ovarian cancer survivor and 2025 Witchery White Shirt Ambassador Jemima Leydon shares her story with this lethal reproductive ...

The Sarasota Memorial Research Institute is participating in a Phase 3 trial of an experimental drug for late-stage ovarian cancer. The drug, Olvi-Vec, is an immunotherapeutic that targets and ...

The Real Housewives of Beverly Hills alum—who is currently battling tumors in her brain and lungs—had a heartbreaking response to a fan who said her stage 4 cancer diagnosis is likely a death ...

A standard diagnostic test for ovarian cancer is less effective in detecting the disease among Black and Native American women, according to a recent study published in JAMA Network Open. The test ...

A new study has identified the protein ADAMTS5 as playing a crucial role in the spread of ovarian cancer cells, offering a potential new target for future treatments. ADAMTS5 functions like a pair ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian cancer. A phase 3 trial found that relacorilant, when combined with ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of ...

ARTISTRY-7 trial data showed nemvaleukin plus Keytruda did not significantly improve overall survival in platinum-resistant ovarian cancer. Mural Oncology will halt nemvaleukin’s development for ...

for platinum-resistant ovarian cancer, and will cease development of the drug for this disease. In ARTISTRY-7, the drug duo failed to show a statistically significant improvement in overall survival ...

USCAP 2025 Risk-Reduction Surgery Benefit in Non-BRCA Ovarian Cancer? A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...